|Reference : Assessment of high sensitive troponin T and I immunoassays in patients with acute chest|
|Scientific congresses and symposiums : Paper published in a journal|
|Human health sciences : Laboratory medicine & medical technology|
Human health sciences : Cardiovascular & respiratory systems
|Assessment of high sensitive troponin T and I immunoassays in patients with acute chest|
|Le Goff, Caroline [Université de Liège - ULg > > Chimie médicale >]|
|Garweg, Christophe [Université de Liège - ULg > Département des sciences cliniques > Département des sciences cliniques >]|
|Laurent, Terry [> >]|
|Kaux, Jean-François [Université de Liège - ULg > Département des sciences cliniques > Département des sciences cliniques >]|
|Deroyer, Céline [Université de Liège - ULg > Département de pharmacie > GIGA-R : Chimie médicale >]|
|Merville, Marie-Paule [Université de Liège - ULg > Département de pharmacie > Chimie médicale >]|
|Melon, Pierre [Université de Liège - ULg > > Cardiologie >]|
|Fillet, Marianne [Université de Liège - ULg > Département de pharmacie > Analyse des médicaments >]|
|Legrand, Victor [Université de Liège - ULg > Département des sciences cliniques > Cardiologie >]|
|Chapelle, Jean-Paul [Université de Liège - ULg > Département de pharmacie > Chimie médicale >]|
|American Association for Clinical Chemistry|
|Abstracts of the Scientific Posters, 2010 AACC Annual Meeting|
|2010 AACC’s Annual Meeting|
|July 25-29, 2010|
|American Association for Clinical Chemistry|
Cardiac troponin I and T are specific markers of myocardial injury that are widely used for
the diagnosis of acute coronary syndrome (ACS). In acute chest pain without ST-segment
elevation, they are used to differentiate unstable angina from non ST-segment elevation
myocardial infarction (NSTEMI). Recently, troponin assays with higher analytical
sensitivities became available to enable the detection of minor myocardial damage and
identify individuals at higher risk for ACS. As a result of its high tissue-specificity, cardiac
troponin T and I are cardio-specific, highly sensitive markers for myocardial damage. The aim
of this study was to evaluate the new higher sensitive troponin (T and I) in patients with stable
angina and acute chest pain without ST-segment elevation.
Methods: Sixty subjects (mean age : 65.5± 11 years), were included: 20 healthy controls, 20
patients with stable angina, 9 with unstable angina (troponin-) and 18 patients with NSTEMI
myocardial infarction (troponin+). The protocol was approved by the ethic committee of the
University of Liège (Belgium). High sensitive troponin T (hsTnT) determination was realized
on heparin plasma by electrochemiluminescence immunoassay on Modular E (Roche
Diagnostic). Troponin I II (TnI II) is a chemiluminescent microparticle immunoassay for the
quantitative determination of cardiac troponin-I in heparine plasma on the ARCHITECT i
System (Abbott Diagnostic). The lower detection limit of these assays was 0.005μg/L for
hsTnT and 0.01μg/L for TnI II.
Stastistical analysis was performed using t test. P value <0.05 was considered significant.
Results: HsTNT levels were 0.003(0.003, 0.004) [median baseline (1st, 3rd quartile)]ng/ml in
controls, 0.0075 (0.00475, 0.014) ng/ml in stable angina, 0.011(0.006, 0.012) ng/ml in
unstable angina and 0.3715 (0.1795, 1.00725) ng/ml in NSTEMI ACS. TnI II levels were 0
(0, 0.001) ng/ml in controls and in patients with stable angina, 0.07 (0.005, 0.014) ng/ml in
unstable angina and 1.4475 (0.0407, 2.656) ng/ml in NSTEMI.
HsTNT and TnI II levels were significantly increased in NSTEMI as compared to control
subjects, patients with stable and unstable angina. TnI II levels were also increased in unstable
angina as compared to controls.
Conclusion: In our population, TnI II was more sensitive than hsTNT to detect minor
myocardial damage in patients with unstable angina as compared to controls. Therefore,
future studies will have to determine whether TnI II might contribute to better risk
stratification and treatment strategy in this group of patients.
|Abstract being selected to be presented at the Genzyme Student Poster Contest at the 2010 AACC Annual Meeting in Anaheim, California.
I do not have any objections to you using this presentation, but please remember that the material is copyrighted by my medical school, and that the intellectual property is recognised as being mine. Therefore, each and every single slide will have to be acknowledged in writing on the slide itself as being mine, and the medical school logo should be displayed (you can copy and paste it from the first slide).
|File(s) associated to this reference|
All documents in ORBi are protected by a user license.